FERNISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FERNISONE (FERNISONE).
FERNISONE is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
| Metabolism | Metabolized primarily by CYP3A4 in the liver to inactive metabolites. |
| Excretion | Renal excretion of unchanged drug and metabolites: ~60% (30% unchanged, 30% metabolites). Biliary/fecal elimination: ~35% (primarily as metabolites). Minor metabolic clearance via CYP3A4. About 5% eliminated in sweat and saliva. |
| Half-life | Terminal elimination half-life: 18-24 hours in healthy adults. In elderly (age >65), half-life increases to 30-36 hours due to reduced renal function. In moderate renal impairment (CrCl 30-60 mL/min), half-life extends to 40-48 hours. Clinical context: requires dose adjustment in renal impairment; steady-state reached in 3-5 days. |
| Protein binding | Approximately 92-96% bound to serum albumin (primarily) and alpha-1-acid glycoprotein (minor). In hypoalbuminemia (e.g., cirrhosis, nephrotic syndrome), free fraction increases significantly, enhancing pharmacodynamic effect. |
| Volume of Distribution | Volume of distribution (Vd): 0.18-0.25 L/kg (12-17.5 L for 70 kg adult). This low Vd indicates limited extravascular distribution, primarily in central compartment (plasma and interstitial fluid). Clinical meaning: reflects poor tissue penetration, consistent with high protein binding; loading dose may not be required. |
| Bioavailability | Oral: 75-85% (tablet) due to first-pass metabolism; reduced to 60-70% with food. Intravenous: 100%. Topical: approximately 5-15% (systemic absorption depends on application area and skin integrity; occlusive dressing increases to 30%.) |
| Onset of Action | Oral immediate-release: 1-2 hours (peak effect at 4-6 hours). Intravenous: 15-30 minutes (rapid onset for acute conditions). Intramuscular: 30-60 minutes. Topical (cream): 2-4 hours for local anti-inflammatory effect. |
| Duration of Action | Oral: 12-24 hours (single dose); with repeated dosing, anti-inflammatory effect persists for duration of therapy. Intravenous: 6-12 hours (acute effect). Topical: 8-12 hours after application. Clinical notes: duration may be prolonged in hepatic impairment due to reduced clearance; for chronic use, duration is limited by cumulative toxicity. |
40 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for any GFR level |
| Liver impairment | Child-Pugh A: 40 mg once daily; Child-Pugh B: 30 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | 0.5 mg/kg orally once daily; maximum 40 mg/day |
| Geriatric use | Initiate at 20 mg orally once daily; titrate based on response and tolerability |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FERNISONE (FERNISONE).
| Breastfeeding | FERNISONE is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5. At maternal doses up to 80 mg/day, infant dose is less than 10% of maternal weight-adjusted dose. However, high doses may cause infant adrenal suppression. Monitor infant for growth and development. Use with caution. |
| Teratogenic Risk | FERNISONE is a corticosteroid with known teratogenic potential in animal studies. In humans, first trimester use is associated with increased risk of cleft lip and palate (odds ratio 3.5). Second and third trimester exposure may lead to intrauterine growth restriction, adrenal suppression, and increased risk of gestational diabetes. Benefits must outweigh risks. |
■ FDA Black Box Warning
None
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to any component","Administration of live or live-attenuated vaccines in immunosuppressed patients"]
| Precautions | ["May cause adrenal suppression with prolonged use","Increased risk of infections","Osteoporosis with long-term use","Hyperglycemia","Growth retardation in children","Cushing's syndrome with high doses"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and adrenal function. Perform serial fetal ultrasounds for growth restriction. Monitor for signs of maternal infection. Assess fetal adrenal function via nonstress test and biophysical profile in third trimester. |
| Fertility Effects | FERNISONE may suppress hypothalamic-pituitary-adrenal axis, potentially leading to menstrual irregularities and impaired ovulation. Reversible upon dose reduction or discontinuation. No direct effect on sperm parameters in males. |